Obesity‐related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension

In light of the worldwide epidemic of obesity, and in recognition of hypertension as a major factor in the cardiovascular morbidity and mortality associated with obesity, The Obesity Society and The American Society of Hypertension agreed to jointly sponsor a position paper on obesity‐related hypertension to be published jointly in the journals of each society. The purpose is to inform the members of both societies, as well as practicing clinicians, with a timely review of the association between obesity and high blood pressure, the risk that this association entails, and the options for rational, evidenced‐based treatment. The position paper is divided into six sections plus a summary as follows: pathophysiology, epidemiology and cardiovascular risk, the metabolic syndrome, lifestyle management in prevention and treatment, pharmacologic treatment of hypertension in the obese, and the medical and surgical treatment of obesity in obese hypertensive patients. Obesity (2012)

[1]  Elizabeth L Hoffman,et al.  The metabolic syndrome. , 2015, South Dakota medicine : the journal of the South Dakota State Medical Association.

[2]  A. Berghold,et al.  Long-term effects of weight-reducing drugs in hypertensive patients. , 2009, The Cochrane database of systematic reviews.

[3]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.

[4]  S A Jebb,et al.  EPODE approach for childhood obesity prevention: methods, progress and international development , 2012, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[5]  G. Ailhaud,et al.  Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. , 2012, The Journal of clinical investigation.

[6]  B. Spiegelman,et al.  A PGC1α-dependent myokine that drives browning of white fat and thermogenesis , 2012, Nature.

[7]  Shingo,et al.  A PGC1-\(\alpha\)-dependent Myokine that Drives Brown-fat-like Development of White Fat and Thermogenesis , 2012 .

[8]  B. Popkin,et al.  Global nutrition transition and the pandemic of obesity in developing countries. , 2012, Nutrition reviews.

[9]  R. Collins,et al.  Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial , 2012, Drugs.

[10]  S. Simpson,et al.  What is the most effective way to maintain weight loss in adults? , 2011, BMJ : British Medical Journal.

[11]  A. Heath,et al.  Prevention of Overweight in Infancy (POI.nz) study: a randomised controlled trial of sleep, food and activity interventions for preventing overweight from birth , 2011, BMC public health.

[12]  F. Greenway,et al.  Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long‐Term Phentermine Pharmacotherapy for Obesity , 2011, Obesity.

[13]  Terence Dwyer,et al.  Childhood adiposity, adult adiposity, and cardiovascular risk factors. , 2011, The New England journal of medicine.

[14]  T. Cole,et al.  Assessing the efficacy of the healthy eating and lifestyle programme (HELP) compared with enhanced standard care of the obese adolescent in the community: study protocol for a randomized controlled trial , 2011, Trials.

[15]  S. Costanzo,et al.  Wine, beer or spirit drinking in relation to fatal and non-fatal cardiovascular events: a meta-analysis , 2011, European Journal of Epidemiology.

[16]  A. Kengne,et al.  Metabolic sequelae of β-blocker therapy: weighing in on the obesity epidemic? , 2011, International Journal of Obesity.

[17]  J. Saxe.  Promoting Healthy Lifestyles and Decreasing Childhood Obesity: Increasing Physician Effectiveness Through Advocacy , 2011, The Annals of Family Medicine.

[18]  R. Fagard,et al.  Impact of Resistance Training on Blood Pressure and Other Cardiovascular Risk Factors: A Meta-Analysis of Randomized, Controlled Trials , 2011, Hypertension.

[19]  John C Mathers,et al.  Tracking of obesity-related behaviours from childhood to adulthood: A systematic review. , 2011, Maturitas.

[20]  Emily M Lindley,et al.  Cognitive and behavioral approaches in the treatment of obesity. , 2011, The Medical clinics of North America.

[21]  M. Martínez-González,et al.  Alcohol consumption and body weight: a systematic review. , 2011, Nutrition reviews.

[22]  Lawrence Joseph,et al.  Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. , 2011, The American journal of medicine.

[23]  D. Mozaffarian,et al.  Changes in diet and lifestyle and long-term weight gain in women and men. , 2011, The New England journal of medicine.

[24]  M. Hagströmer,et al.  A randomised controlled trial for overweight and obese parents to prevent childhood obesity - Early STOPP (STockholm Obesity Prevention Program) , 2011, BMC public health.

[25]  S. Davis,et al.  Pramlintide and the treatment of diabetes: a review of the data since its introduction , 2011, Expert opinion on pharmacotherapy.

[26]  K. Gadde,et al.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[27]  Lawrence H. Kushi,et al.  Following Cancer Prevention Guidelines Reduces Risk of Cancer, Cardiovascular Disease, and All-Cause Mortality , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[28]  D. Panagiotakos,et al.  The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. , 2011, Journal of the American College of Cardiology.

[29]  C. Abraham,et al.  Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions , 2011, BMC public health.

[30]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[31]  Willem van Mechelen,et al.  Sedentary behaviors and health outcomes among adults: a systematic review of prospective studies. , 2011, American journal of preventive medicine.

[32]  G. Foster,et al.  Dietary approaches to the treatment of obesity. , 2005, The Psychiatric clinics of North America.

[33]  Ross Ward,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure , 2011 .

[34]  A. Berghold,et al.  Long-term effects of weight-reducing diets in hypertensive patients. , 2011, The Cochrane database of systematic reviews.

[35]  Morbidity and Mortality Weekly Report , 2022 .

[36]  D. L'Allemand-Jander,et al.  Clinical diagnosis of metabolic and cardiovascular risks in overweight children: early development of chronic diseases in the obese child , 2010, International Journal of Obesity.

[37]  D. Schoeller,et al.  Insufficient Sleep Undermines Dietary Efforts to Reduce Adiposity , 2010, Annals of Internal Medicine.

[38]  Jeremy D. Akers,et al.  Translational research: bridging the gap between long-term weight loss maintenance research and practice. , 2010, Journal of the American Dietetic Association.

[39]  P. Deedwania,et al.  The Role of Renin-Angiotensin Agents in Altering the Natural History of Type 2 Diabetes Mellitus , 2010, Current cardiology reports.

[40]  F. Greenway,et al.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2010, The Lancet.

[41]  C. Behre,et al.  Feasibility of Bariatric Surgery as a Strategy for Secondary Prevention in Cardiovascular Disease: A Report from the Swedish Obese Subjects Trial , 2010, Journal of obesity.

[42]  Alan Bauck,et al.  Associations of Internet Website Use With Weight Change in a Long-term Weight Loss Maintenance Program , 2010, Journal of medical Internet research.

[43]  K. Linde,et al.  Multifactorial Lifestyle Interventions in the Primary and Secondary Prevention of Cardiovascular Disease and Type 2 Diabetes Mellitus—A Systematic Review of Randomized Controlled Trials , 2010, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[44]  Over-the-counter weight loss with orlistat? , 2010, Evidence Based Nursing.

[45]  R. Berria,et al.  Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database , 2010, Diabetes Care.

[46]  T. Fujita.  Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. , 2010, Hypertension.

[47]  R. Rychlik,et al.  New-onset diabetes and antihypertensive treatment , 2010, GMS health technology assessment.

[48]  J. Sowers,et al.  Best Strategies for Hypertension Management in Type 2 Diabetes and Obesity , 2010, Current diabetes reports.

[49]  F. Rubino,et al.  Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus , 2010, Nature Reviews Endocrinology.

[50]  P. Lin,et al.  Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. , 2010, Archives of internal medicine.

[51]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2008. , 2010, JAMA.

[52]  Gerald S Berenson.  Cardiovascular health promotion for children: a model for a Parish (County)-wide program (implementation and preliminary results). , 2010, Preventive cardiology.

[53]  W. D. van Marken Lichtenbelt,et al.  Cold-activated brown adipose tissue in healthy men. , 2009, The New England journal of medicine.

[54]  J. Jakicic.  The Effect of Physical Activity on Body Weight , 2009, Obesity.

[55]  H. Rothnie,et al.  Long-Term Weight Loss From Lifestyle Intervention Benefits Blood Pressure?: A Systematic Review , 2009, Hypertension.

[56]  L. Beilin,et al.  Longitudinal Modelling of Body Mass Index from Birth to 14 Years , 2009, Obesity Facts.

[57]  L. Appel,et al.  ASH Position Paper: Dietary Approaches to Lower Blood Pressure , 2009, Journal of clinical hypertension.

[58]  A. Garfield,et al.  Role of central melanocortin pathways in energy homeostasis , 2009, Trends in Endocrinology & Metabolism.

[59]  J. Sowers,et al.  Nebivolol in Obese and Non‐Obese Hypertensive Patients , 2009, Journal of clinical hypertension.

[60]  R Bethene Ervin,et al.  Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. , 2009, National health statistics reports.

[61]  C. Choi,et al.  Estimating the probability of stroke in Korean hypertensive patients visiting tertiary hospitals using a risk profile from the framingham study , 2009, BMC neurology.

[62]  J. Cutler,et al.  Suboptimal nutritional intake for hypertension control in 4 ethnic groups. , 2009, Archives of internal medicine.

[63]  R. Whitaker,et al.  Prevalence of obesity among US preschool children in different racial and ethnic groups. , 2009, Archives of pediatrics & adolescent medicine.

[64]  A. Bomback,et al.  Interaction of Aldosterone and Extracellular Volume in the Pathogenesis of Obesity-Associated Kidney Disease: A Narrative Review , 2009, American Journal of Nephrology.

[65]  Hong Wang,et al.  The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action , 2009, Diabetologia.

[66]  S. Linas,et al.  The role of obesity in the pathogenesis of hypertension , 2009, Nature Clinical Practice Nephrology.

[67]  F. Stanley,et al.  Synergy Between Adiposity, Insulin Resistance, Metabolic Risk Factors, and Inflammation in Adolescents , 2009, Diabetes Care.

[68]  Emily M Lindley,et al.  Cognitive and behavioral approaches in the treatment of obesity. , 2008, Endocrinology and metabolism clinics of North America.

[69]  G. Bray.  Lifestyle and pharmacological approaches to weight loss: efficacy and safety. , 2008, The Journal of clinical endocrinology and metabolism.

[70]  T. Goodfriend.  Obesity, sleep apnea, aldosterone, and hypertension , 2008, Current hypertension reports.

[71]  G. Mancia,et al.  The metabolic syndrome in hypertension: European society of hypertension position statement , 2008, Journal of hypertension.

[72]  L. Aronne,et al.  Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity , 2008, Diabetes Care.

[73]  L. Macconell,et al.  Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Clinical therapeutics.

[74]  F. Salvi,et al.  Renin–angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans , 2008, Journal of hypertension.

[75]  Alan Bauck,et al.  Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. , 2008, JAMA.

[76]  Z. Wang,et al.  Closing the energy gap to prevent weight gain in China , 2008, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[77]  G. Bray,et al.  The metabolic syndrome : Epidemiology, Clinical Treatment, and Underlying mechanisms , 2008 .

[78]  Hyon K. Choi,et al.  Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. , 2008, Arthritis and rheumatism.

[79]  C. Champagne,et al.  Effects of PREMIER Lifestyle Modifications on Participants With and Without the Metabolic Syndrome , 2007, Hypertension.

[80]  Takahiko Nakagawa,et al.  Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. , 2007, The American journal of clinical nutrition.

[81]  K. Fujioka,et al.  Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. , 2007, The Journal of clinical endocrinology and metabolism.

[82]  Robert A. Phillips,et al.  Body Weight Changes with β-Blocker Use: Results from GEMINI , 2007 .

[83]  M. Lee,et al.  Acute effects of cigarette smoking on arterial stiffness and blood pressure in male smokers with hypertension. , 2007, American journal of hypertension.

[84]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[85]  G. Bray,et al.  Drug treatment of the overweight patient. , 2007, Gastroenterology.

[86]  N. Cook,et al.  Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP) , 2007, BMJ : British Medical Journal.

[87]  Liviu Klein,et al.  Consistently Stable or Decreased Body Mass Index in Young Adulthood and Longitudinal Changes in Metabolic Syndrome Components: The Coronary Artery Risk Development in Young Adults Study , 2007, Circulation.

[88]  L. Palmer,et al.  Perinatal and childhood origins of cardiovascular disease , 2007, International Journal of Obesity.

[89]  D. Klonoff,et al.  Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. , 2007, Clinical therapeutics.

[90]  Janet B McGill,et al.  Body weight changes with beta-blocker use: results from GEMINI. , 2007, The American journal of medicine.

[91]  M. Beydoun,et al.  The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. , 2007, Epidemiologic reviews.

[92]  T. Nakagawa,et al.  Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. , 2007, American journal of physiology. Renal physiology.

[93]  C. Del Mar,et al.  Exercise for overweight or obesity. , 2006, The Cochrane database of systematic reviews.

[94]  L. Appel,et al.  One year follow-up of overweight and obese hypertensive adults following intensive lifestyle therapy. , 2006, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[95]  R. Fagard.  EXERCISE IS GOOD FOR YOUR BLOOD PRESSURE: EFFECTS OF ENDURANCE TRAINING AND RESISTANCE TRAINING , 2006, Clinical and experimental pharmacology & physiology.

[96]  I. Puddey,et al.  ALCOHOL IS BAD FOR BLOOD PRESSURE , 2006, Clinical and experimental pharmacology & physiology.

[97]  Dennis D. Kim,et al.  Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes , 2006, Diabetes, obesity & metabolism.

[98]  S. Srinivasan,et al.  Changes in Metabolic Syndrome Variables Since Childhood in Prehypertensive and Hypertensive Subjects: The Bogalusa Heart Study , 2006, Hypertension.

[99]  G. Mancia,et al.  Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial , 2006, Journal of hypertension.

[100]  Carlos Iribarren,et al.  Body Mass Index and Risk for End-Stage Renal Disease , 2006, Annals of Internal Medicine.

[101]  Yoon-Ho Choi,et al.  Serum Uric Acid Is Associated With Microalbuminuria in Prehypertension , 2006, Hypertension.

[102]  Michael Proschan,et al.  Effects of Comprehensive Lifestyle Modification on Diet, Weight, Physical Fitness, and Blood Pressure Control: 18-Month Results of a Randomized Trial , 2006, Annals of Internal Medicine.

[103]  Matthias Briel,et al.  Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.

[104]  P. Wolf,et al.  The lifetime risk of stroke: estimates from the Framingham Study. , 2006, Stroke.

[105]  M. Laakso,et al.  Metabolic syndrome: To be or not to be? , 2006, Annals of medicine.

[106]  D. Bessesen.  Meta-analysis: Pharmacologic Treatment of Obesity , 2006 .

[107]  Arya M. Sharma,et al.  The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. , 2006, Journal of the cardiometabolic syndrome.

[108]  Seppo Lehto,et al.  Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. , 2005, Diabetes care.

[109]  N. Hollenberg,et al.  Body Mass Index and Angiotensin-Dependent Control of the Renal Circulation in Healthy Humans , 2005, Hypertension.

[110]  C. McCulloch,et al.  Which Comes First—Renal Dysfunction or High Blood Pressure? Elevated Blood Pressure and Risk of End-Stage Renal Disease in Subjects without Baseline Kidney Disease. Arch Intern Med 165: 923–928, 2005 , 2005 .

[111]  J. Douketis,et al.  Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice , 2005, International Journal of Obesity.

[112]  N. Day,et al.  Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study. , 2005, Obesity research.

[113]  D. Lloyd‐Jones,et al.  Hypertension in adults across the age spectrum: current outcomes and control in the community. , 2005, JAMA.

[114]  R. D'Agostino,et al.  Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study. , 2005, Archives of internal medicine.

[115]  V. Burke,et al.  Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial , 2005, Journal of hypertension.

[116]  Abdullah Al Mamun,et al.  Effect of Body Mass Index Changes Between Ages 5 and 14 on Blood Pressure at Age 14: Findings From a Birth Cohort Study , 2005, Hypertension.

[117]  A. Avenell,et al.  Effects of Weight Loss in Overweight/Obese Individuals and Long-Term Hypertension Outcomes: A Systematic Review , 2005, Hypertension.

[118]  Fred W. Turek,et al.  Obesity and Metabolic Syndrome in Circadian Clock Mutant Mice , 2005, Science.

[119]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[120]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[121]  C. McCulloch,et al.  Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. , 2005, Archives of internal medicine.

[122]  L. Kaplan,et al.  Pharmacologic therapies for obesity. , 2010, Gastroenterology clinics of North America.

[123]  C. Reid,et al.  Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. , 2005, Journal of hypertension.

[124]  Arya M. Sharma,et al.  Weight Loss and the Renin-Angiotensin-Aldosterone System , 2005, Hypertension.

[125]  F. Turek,et al.  Sleepless in America: a pathway to obesity and the metabolic syndrome? , 2005, Archives of internal medicine.

[126]  N. Cook,et al.  Sodium reduction for hypertension prevention in overweight adults: further results from the Trials of Hypertension Prevention Phase II , 2005, Journal of Human Hypertension.

[127]  Claude Bouchard,et al.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. , 2004, The New England journal of medicine.

[128]  Rachel Leproult,et al.  Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. , 2004, The Journal of clinical endocrinology and metabolism.

[129]  O G Kolterman,et al.  Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[130]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. , 2004, Diabetes care.

[131]  Youfa Wang,et al.  The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. , 2004, Archives of internal medicine.

[132]  Henry Buchwald,et al.  Bariatric surgery: a systematic review and meta-analysis. , 2004, JAMA.

[133]  M. Kosch,et al.  Elevated sympathetic nerve activity: the link between low birth size and adult-onset metabolic syndrome? , 2004, Journal of hypertension.

[134]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[135]  M K Campbell,et al.  Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. , 2004, Health technology assessment.

[136]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[137]  Robert Wolk,et al.  Obesity, Sleep Apnea, and Hypertension , 2003, Hypertension.

[138]  A. E. Caballero,et al.  Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. , 2003, Obesity research.

[139]  Diederick E. Grobbee,et al.  Influence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials , 2003, Hypertension.

[140]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[141]  V. Somers,et al.  Sympathetic nerve activity in obstructive sleep apnoea. , 2003, Acta physiologica Scandinavica.

[142]  C. Weyer,et al.  Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. , 2003, Diabetes care.

[143]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[144]  T. Funahashi,et al.  Decreased plasma adiponectin concentration in patients with essential hypertension. , 2003, American journal of hypertension.

[145]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[146]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[147]  D. Barker.  Fetal programming of coronary heart disease , 2002, Trends in Endocrinology & Metabolism.

[148]  Megan Jehn,et al.  Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). , 2002, Hypertension.

[149]  Ralph B D'Agostino,et al.  Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. , 2002, Archives of internal medicine.

[150]  M. Nieminen,et al.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , 2002, Journal of hypertension.

[151]  S. Goodwin,et al.  The Practical Guide to the Identification, Evaluation and Treatment of Overweight and Obesity in Adults , 2002 .

[152]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[153]  W. Poston,et al.  Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials , 2002, International Journal of Obesity.

[154]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[155]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[156]  Alan C. Wilson,et al.  Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). , 2001, Archives of internal medicine.

[157]  L. Landsberg.  Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) , 2001, Journal of hypertension.

[158]  T. Pischon,et al.  Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain , 2001 .

[159]  N. Milas,et al.  Long-Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II , 2001, Annals of Internal Medicine.

[160]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. , 2001, The New England journal of medicine.

[161]  T. Pischon,et al.  Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. , 2001, Hypertension.

[162]  E. Waters,et al.  Interventions for preventing obesity in children. , 2001, The Cochrane database of systematic reviews.

[163]  J. Eriksson,et al.  Fetal and Childhood Growth and Hypertension in Adult Life , 2000, Hypertension.

[164]  K. Kukkonen-Harjula,et al.  Does physical activity prevent weight gain – a systematic review , 2000, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[165]  C. Lucas,et al.  Orlistat in the long-term treatment of obesity in primary care settings. , 2000, Archives of family medicine.

[166]  M. Mäkelä,et al.  Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors , 2000, Annals of medicine.

[167]  Orton,et al.  EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION ( DASH ) DIET , 2000 .

[168]  S. Rössner,et al.  Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. , 2000, Obesity research.

[169]  S. Ebrahim,et al.  Multiple risk factor interventions for primary prevention of coronary heart disease. , 2000, The Cochrane database of systematic reviews.

[170]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[171]  E. van Cauter,et al.  Sleep as a Mediator of the Relationship between Socioeconomic Status and Health: A Hypothesis , 1999, Annals of the New York Academy of Sciences.

[172]  N. Rothwell,et al.  Hypothalamic control of feeding , 1999, Current Opinion in Neurobiology.

[173]  K. Spiegel,et al.  Impact of sleep debt on metabolic and endocrine function , 1999, The Lancet.

[174]  D. Levy,et al.  Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. , 1999, Archives of internal medicine.

[175]  G. Yoshino,et al.  Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index. , 1999, Journal of hypertension.

[176]  C. Mantzoros.  The Role of Leptin in Human Obesity and Disease: A Review of Current Evidence , 1999, Annals of Internal Medicine.

[177]  P. J. Larsen,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Central Administration of Leptin Inhibits Food Intake and Activates the Sympathetic Nervous System in Rhesus Macaques* , 2022 .

[178]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[179]  G. Mancia,et al.  Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. , 1998, Circulation.

[180]  R. Vandongen,et al.  A controlled trial of health promotion programs in 11-year-olds using physical activity "enrichment" for higher risk children. , 1998, The Journal of pediatrics.

[181]  D. Johnston,et al.  The Effects of Metformin on Glycemic Control and Serum Lipids in Insulin-Treated NIDDM Patients With Suboptimal Metabolic Control , 1998, Diabetes Care.

[182]  J. Hall,et al.  Chronic leptin infusion increases arterial pressure. , 1998, Hypertension.

[183]  Huiqing Lu,et al.  Intracerebroventricular Leptin Increases Lumbar and Renal Sympathetic Nerve Activity and Blood Pressure in Normal Rats , 1997, Diabetes.

[184]  Y. Miyazaki,et al.  High plasma immunoreactive leptin level in essential hypertension. , 1997, American journal of hypertension.

[185]  A. Mark,et al.  Receptor-mediated regional sympathetic nerve activation by leptin. , 1997, The Journal of clinical investigation.

[186]  D. Levy,et al.  Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. , 1997, Circulation.

[187]  G. Bray,et al.  A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. , 1997, The New England journal of medicine.

[188]  W. Garvey,et al.  The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. , 1997, The Journal of clinical endocrinology and metabolism.

[189]  N. Cook,et al.  Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group. , 1997, The American journal of clinical nutrition.

[190]  V. Burke,et al.  Exercise and weight control in sedentary overweight men: effects on clinic and ambulatory blood pressure , 1996, Journal of hypertension.

[191]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[192]  L. Beilin,et al.  Clustering of Cardiovascular Risk Factors in Australian Adolescents: Association with Dietary Excesses and Deficiencies , 1995, Journal of cardiovascular risk.

[193]  L. Kuller,et al.  Impact of systolic and diastolic blood pressure on cardiovascular mortality , 1995 .

[194]  A. Mark,et al.  Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels , 1995, Journal of hypertension.

[195]  R. DeFronzo,et al.  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.

[196]  G. Mancia,et al.  Sympathetic activation in obese normotensive subjects. , 1995, Hypertension.

[197]  P Whelton,et al.  Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. , 1995, Hypertension.

[198]  L. Beilin,et al.  VEGETARIAN DIET COMPONENTS, PROTEIN AND BLOOD PRESSURE: WHICH NUTRIENTS ARE IMPORTANT? , 1995, Clinical and experimental pharmacology & physiology.

[199]  R. Vandongen,et al.  A controlled evaluation of a fitness and nutrition intervention program on cardiovascular health in 10- to 12-year-old children. , 1995, Preventive medicine.

[200]  P. Vollenweider,et al.  Body fat and sympathetic nerve activity in healthy subjects. , 1994, Circulation.

[201]  B. Metzger,et al.  Fetal Hyperinsulinism in Offspring of Diabetic Mothers , 1993, Annals of the New York Academy of Sciences.

[202]  J. Neaton,et al.  Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. , 1993, Archives of internal medicine.

[203]  A. Dyer,et al.  Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. , 1993, Cardiology.

[204]  R. Vandongen,et al.  Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. , 1992, Hypertension.

[205]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[206]  R. Troisi,et al.  Relation of Obesity and Diet to Sympathetic Nervous System Activity , 1991, Hypertension.

[207]  R B D'Agostino,et al.  Probability of stroke: a risk profile from the Framingham Study. , 1991, Stroke.

[208]  P. Vokonas,et al.  Body fat distribution, blood pressure, and hypertension. A prospective cohort study of men in the normative aging study. , 1990, Annals of epidemiology.

[209]  M. Saad,et al.  Insulin resistance in essential hypertension. , 1990, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[210]  The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Hypertension Prevention Trial Research Group. , 1990, Archives of internal medicine.

[211]  V. Katch,et al.  The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. , 1989, The New England journal of medicine.

[212]  J. Hall,et al.  Regulation of arterial pressure: role of pressure natriuresis and diuresis. , 1986, Federation proceedings.

[213]  L. Landsberg.  Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. , 1986, The Quarterly journal of medicine.

[214]  H. Halkin,et al.  Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. , 1985, The Journal of clinical investigation.

[215]  K. Pennert,et al.  Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. , 1984, British medical journal.

[216]  P. Björntorp,et al.  Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. , 1984, British medical journal.

[217]  A. Kissebah,et al.  Relationship of body fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy obese women. , 1983, The Journal of laboratory and clinical medicine.

[218]  L. Sjöström,et al.  Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. , 1983, The Journal of clinical investigation.

[219]  A. Kissebah,et al.  Relation of body fat distribution to metabolic complications of obesity. , 1982, The Journal of clinical endocrinology and metabolism.

[220]  J W Rowe,et al.  Effect of Insulin and Glucose Infusions on Sympathetic Nervous System Activity in Normal Man , 1981, Diabetes.

[221]  R. DeFronzo,et al.  Insulin and renal sodium handling: clinical implications. , 1981, International journal of obesity.

[222]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[223]  W. Kannel,et al.  The relation of adiposity to blood pressure and development of hypertension. The Framingham study. , 1967, Annals of internal medicine.

[224]  J. Vague,et al.  The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. , 1956, The American journal of clinical nutrition.

[225]  R D Rudolf,et al.  High Blood Pressure , 1937, Canadian Medical Association journal.